ClinicalTrials.gg
RecruitingNCT07030257Updated Feb 18, 2026

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of CP-383 in Solid Tumor Malignancies, Colorectal Carcinoma and Small Cell Lung Cancer ( SCLC ), sponsored by Tasca Therapeutics. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Tasca Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
622nd of 1,934
150 · median 64
Started
2025
with 143 others
Phase 1/2
267 of 2,342
67 open now
Primary completion
2028-08
later than 457 of 627 live
Registered
2,150th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 622nd largest by planned enrollment of the 1,934 interventional ones that give a count, is one of 144 that started in 2025, is one of 267 in phase 1/2, reaches primary completion later than 457 of the 627 other live ones, and was the 2,150th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are:

  • Does CP-383 slow or stop the growth of cancer in patients with advanced cancer
  • What medical problems do participants have when taking CP-383 Researchers will test CP-383 in all kinds of cancers at various dose levels to determine what the best dose is to study further. Researchers will also see if certain cancers that have gene mutations respond better to CP-383

Participants will:

  • Take CP-383 every day by mouth until the researcher learns whether CP-383 is helping slow or reduce the cancer growth
  • Visit the clinic weekly for the first 6 weeks for checkups and tests
  • Visit the clinic every 3 weeks thereafter for checkups and tests
03

Conditions studied

  • Solid Tumor Malignancies
  • Colorectal Carcinoma
  • Small Cell Lung Cancer ( SCLC )
  • Head and Neck (HNSCC)
  • Bladder Cancer
  • Non-Small Cell Lung Cancer
  • Pancreatic Cancer, Advanced or Metastatic

Keywords

  • Phase 1
  • Dose Escalation
  • Dose Expansion
  • Loss of Function
  • FAT1
  • P300
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Measurable or non measurable cancer that the research can assess for changes
  • Not eligible or able to take existing standard therapies for cancer
  • Availability of a part of a tumor for laboratory testing or willing to have a safe taken from a tumor
  • Diagnosed with locally advanced, recurrent or incurable disease
  • Part 1: any solid tumor (with the exception of brain cancer) that has progressed, standard therapy is no longer or has not helped the cancer, or is too toxic and for whom a clinical trial is an option for continued treatment
  • Part 1: specific advanced, metastatic tumor types will also be enrolled: colorectal cancer, small cell lung cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer - some of these will have a specific gene mutation in the cancer
  • Part 1: selected solid tumor cancer types (with the exception of brain cancers) that have a specific gene mutation in the cancer
  • Part 2: specific advanced, metastatic tumor types will also be enrolled: colorectal cancer, small cell lung cancer, head and neck cancer - some of these will have a specific gene mutation in the cancer

    _ Part 2: selected solid tumor cancer types (with the exception of brain cancers) that have a specific gene mutation in the cancer

  • Adequate blood and urine lab tests
  • Women and men of with adequate
  • Provides written
  • Willing to comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • Inability to swallow pills
  • Known history of , , unless cured, controlled with undetectable viral load
  • Active tumor in the brain
  • liver disease
  • Significant gastrointestinal diseases
  • History of other cancer within past 5 years with certain exceptions for cancers that are likely cured
  • Significant cardiac disease
  • Other diseases that are not well controlled that could make taking the drug unsafe
  • pregnant or lactating females
  • Exposure to certain anti-cancer or other drugs within a certain period before the start of study drug
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    CP-383, single daily oral capsule, 0.8 mg

    Drug: CP-383

  • Experimental
    Dose Level 2

    CP-383, single daily oral capsule, 1.6 mg

    Drug: CP-383

  • Experimental
    Dose Level 3

    CP-383, single daily oral capsule, 3.0 mg

    Drug: CP-383

  • Experimental
    Dose Level 4

    CP-383, single daily oral capsule, 5.0 mg

    Drug: CP-383

  • Experimental
    Dose Level 5

    CP-383, single daily oral capsule, 8.0 mg

    Drug: CP-383

  • Experimental
    Dose Level 6

    CP-383, single daily oral capsule, 12 mg

    Drug: CP-383

  • Experimental
    Expansion Arm 1

    Expansion in selected tumor type at recommended Phase 2 Dose of CP-383

    Drug: CP-383

  • Experimental
    Expansion Arm 2

    Expansion in selected tumor type at recommended Phase 2 Dose of CP-383

    Drug: CP-383

  • Experimental
    Expansion Arm 3

    Expansion in selected tumor type at recommended Phase 2 Dose of CP-383

    Drug: CP-383

  • Experimental
    Expansion Arm 4

    Expansion in selected tumor type at recommended Phase 2 Dose of CP-383

    Drug: CP-383

Interventions

  • DrugCP-383

    Novel anti-cancer agent inhibiting pyrimidine synthesis in cancer cells

06

What researchers measure

Primary outcomes

  1. Part 1: Determine the maximum tolerated dose (MTD)

    Determine the MTD of CP-383 in subjects with advanced solid tumors

    Time frame: 21 days

  2. Part 2: Evaluate the efficacy of CP-383 at the recommended phase 2 dose in selected tumor types

    Objective response rate assessed by the investigator according to RECIST

    Time frame: From enrollment through study completion, an average of 1 year

Secondary outcomes

  1. Part 1: Determine the pharmacokinetics parameters of CP-383

    Assess standard PK parameters including Cmax

    Time frame: From enrollment through study completion, an average of 1 year

  2. Part 1: Determine the pharmacokinetics parameters of CP-383

    Assess standard PK parameters including tmax

    Time frame: From enrollment through study completion, an average of 1 year

  3. Part 1: Determine the pharmacokinetics parameters of CP-383

    Assess standard PK parameters including AUC

    Time frame: From enrollment through study completion, an average of 1 year

  4. Part 1: Assess safety and tolerability of CP-383 in participants with advanced solid tumors

    Incidence and severity of Adverse events and changes in test results

    Time frame: From enrollment through study completion, an average of 1 year

  5. Part 2: Evaluate safety and tolerability of CP-383 at the recommended Phase 2 dose in selected tumor types

    Incidence of AEs and changes in test results

    Time frame: From enrollment through study completion, an average of 1 year

  6. Part 2: Evaluate the efficacy of CP-383 at the recommended phase 2 dose in selected tumor types

    Evaluate duration of response

    Time frame: From enrollment through study completion, an average of 1 year

  7. Part 2: Evaluate the efficacy of CP-383 at the recommended phase 2 dose in selected tumor types

    Evaluate disease control as determined by Objective response of CR, PR or SD for at least 6 months

    Time frame: From enrollment through study completion, an average of 1 year

  8. Part 2: Evaluate the efficacy of CP-383 at the recommended phase 2 dose in selected tumor types

    Evaluate progression free survival

    Time frame: From enrollment through study completion, an average of 1 year

  9. Part 2: Evaluate the efficacy of CP-383 at the recommended phase 2 dose in selected tumor types

    Evaluate overall survival

    Time frame: From enrollment through study completion, an average of 1 year

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2028, 35 months after the start.

Of 159 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 35 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
Jun 22, 2025
StartActual
Aug 27, 2025
Primary completionEst.
Aug 15, 2028
CompletionEst.
Feb 2029
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07030257
Lead sponsor
Tasca Therapeutics
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Aug 27, 2025
Primary completion
Aug 15, 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Feb 18, 2026

Study contacts

Tasca Therapeutics
Contact
trials@tascatx.com
617-430-7109

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion